FluBHPVE6E7 / Bluesky Immuotherap - LARVOL DELTA

Phase 1 Dose-escalation Study of FluBHPVE6E7 in HPV16-infected Women (clinicaltrials.gov) - P1 | N=20 | Recruiting | Sponsor: BlueSky Immunotherapies GmbH | Trial completion date: Nov 2024 ➔ Nov 2025 | Trial primary completion date: Sep 2024 ➔ Sep 2025

Trial completion date • Trial primary completion date • Cervical Cancer • Human Papillomavirus Infection • Infectious Disease • Oncology • Solid Tumor

BS-FU01 Follow-Up Study of FluBHPVE6E7 Study Subjects (clinicaltrials.gov) - P=N/A | N=25 | Completed | Sponsor: BlueSky Immunotherapies GmbH | Enrolling by invitation ➔ Completed | N=200 ➔ 25

Enrollment change • Trial completion • Human Papillomavirus Infection • Infectious Disease

Phase 1 Clinical Trial of FluBHPVE6E7 Immunotherapy for HPV16-Associated Oropharyngeal Cancer (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: BlueSky Immunotherapies GmbH

New P1 trial • Head and Neck Cancer • Oncology • Oropharyngeal Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

BS-FU01 Follow-Up Study of FluBHPVE6E7 Study Subjects (clinicaltrials.gov) - P=N/A | N=200 | Enrolling by invitation | Sponsor: BlueSky Immunotherapies GmbH | Trial completion date: Oct 2024 ➔ Jan 2025 | Trial primary completion date: Oct 2024 ➔ Jan 2025

Trial completion date • Trial primary completion date • Human Papillomavirus Infection • Infectious Disease

Phase 1 Dose-escalation Study of FluBHPVE6E7 in HPV16-infected Women (clinicaltrials.gov) - P1 | N=20 | Recruiting | Sponsor: BlueSky Immunotherapies GmbH | Not yet recruiting ➔ Recruiting | Trial completion date: Jun 2024 ➔ Nov 2024 | Trial primary completion date: Apr 2024 ➔ Sep 2024

Enrollment open • Trial completion date • Trial primary completion date • Cervical Cancer • Human Papillomavirus Infection • Infectious Disease • Oncology • Solid Tumor • IFNG

Phase 1 Dose-escalation Study of FluBHPVE6E7 in HPV16-infected Women (clinicaltrials.gov) - P1 | N=20 | Not yet recruiting | Sponsor: BlueSky Immunotherapies GmbH | Initiation date: Apr 2023 ➔ Aug 2023

Trial initiation date • Cervical Cancer • Human Papillomavirus Infection • Infectious Disease • Oncology • Solid Tumor • IFNG

Study of FluBHPVE6E7 in HPV-16 Infected Women (clinicaltrials.gov) - P1 | N=28 | Completed | Sponsor: BlueSky Immunotherapies GmbH | Active, not recruiting ➔ Completed

Cytology • Trial completion • Human Papillomavirus Infection • Infectious Disease • CD4 • CD8 • IFNG

Phase 1 Dose-escalation Study of FluBHPVE6E7 in HPV16-infected Women (clinicaltrials.gov) - P1 | N=20 | Not yet recruiting | Sponsor: BlueSky Immunotherapies GmbH

New P1 trial • Cervical Cancer • Infectious Disease • Oncology • Solid Tumor • IFNG

Study of FluBHPVE6E7 in HPV-16 Infected Women (clinicaltrials.gov) - P1 | N=36 | Active, not recruiting | Sponsor: BlueSky Immunotherapies GmbH | Recruiting ➔ Active, not recruiting | Trial primary completion date: Dec 2022 ➔ Mar 2023

Enrollment closed • Trial primary completion date • Infectious Disease • CD4 • CD8 • IFNG

BS-FU01 Follow-Up Study of FluBHPVE6E7 Study Subjects (clinicaltrials.gov) - P=N/A | N=200 | Enrolling by invitation | Sponsor: BlueSky Immunotherapies GmbH | Trial completion date: Mar 2022 ➔ Oct 2024 | Trial primary completion date: Mar 2022 ➔ Oct 2024

Trial completion date • Trial primary completion date • Infectious Disease • CD4 • CD8 • IFNG